New Paper Looks into Patient-Derived Xenograft Models

Acredit’s Karianne Giller Fleten has published a paper entitled “Experimental treatment of mucinous peritoneal metastases using patient-derived xenograft models”.  In her paper, Karianne used mouse models of human disease to look into the potential efficacy of four different drug therapies (oxaliplatin, irinotecan, cabazitaxel, and regorafenib/capecitabine) on peritoneal metastases. The results support the continued exploration of intraperitoneal treatment protocols for peritoneal metastases with oxaliplatin remaining and cabazitaxel emerging as the most interesting candidates for further studies.

You can read Karianne’s paper here.